Chong Zhong
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, China
Keynote: Surgery Curr Res
The aim of this study is to compare the clinical outcomes following hepatic resection (HR) versus transarterial chemoembolization (TACE) for UICC (the Union for International Cancer Control) stage (7th) T3 HCC (hepatocellular carcinoma). From 2005 to 2013, 1179 patients who underwent HR or TACE were divided into two groups, HR (n=280) or TACE (n=899). The propensity model matched 244 patients in HR and TACE group, respectively, for further analyses. After matching, medium overall survival, 1, 3, and 5-year OS (overall survival) rates in TACE group were 11.8 months (95%CI, 9.9, 13.7), 49.6%, 16.5%, and 8.4%, respectively, whereas HR group were 17.8 months (95% CI, 14.8-20.8), 63.1%, 33.3%, and 26.4%, respectively; (P<0.01). Patients in HR group were more likely to developed pleural effusion. Multivariate analysis indicated that PT, tumor size, tumor numbers, UICC stage, and initial treatment were independent prognostic factors. This study revealed hepatic resection was safe and yielded a survival benefic compared with TACE in UICC stage T3 HCC patients. HR seemed to represent the optimal therapy strategy and should be recommended as a preferable treatment for the management of UICC stage T3 HCC.
Recent Publications
1. Zhong C et al. (2017) The Chinese medicine, Jianpi Huayu Decoction, inhibits the epithelial mesenchymal transition via the regulation of the Smad3/Smad7 cascade. Am. J Transl. Res. 9(6):2694-2711.
2. Zhong C et al. (2015) MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. Int. J Clin. Exp. Pathol. 8(9):9922-9931.
3. Zhong C et al. (2012) Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepatogastroenterology. 59(113):93-97.
4. Zhong C et al. (2009) A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res. Clin. Oncol. 135(10):1437-1445.
Chong Zhong, MD, PhD has his expertise in surgical oncology and minimally invasive surgery in hepatobiliary and pancreatic surgery in the Department of Surgery at The First Affiliated Hospital of Guangzhou University of Chinese Medicine, China. His clinical interest is hepatobiliary and pancreatic surgery. He has been involved in cancer research for more than ten years. His researches focus on liver cancer and epithelial-mesenchymal transition and signal transduction pathway. His researches received supports from National Natural Science Foundation of China.
E-mail: sumszhong@yahoo.com
